Quince Therapeutics, Inc.
QNCX
$1.63
$0.021.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -30.22% | 168.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.50% | 69.98% | |||
| Operating Income | 23.50% | -69.98% | |||
| Income Before Tax | -6.67% | -20.34% | |||
| Income Tax Expenses | 42.55% | 571.43% | |||
| Earnings from Continuing Operations | -6.78% | -20.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.78% | -20.65% | |||
| EBIT | 23.50% | -69.98% | |||
| EBITDA | 23.58% | -69.92% | |||
| EPS Basic | -0.53% | -20.17% | |||
| Normalized Basic EPS | -11.54% | -65.50% | |||
| EPS Diluted | -0.53% | -20.17% | |||
| Normalized Diluted EPS | -11.54% | -65.50% | |||
| Average Basic Shares Outstanding | 6.25% | 0.37% | |||
| Average Diluted Shares Outstanding | 6.25% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||